Abilify Tardive Dyskinesia Suit Dismissed Because Label Warns Of Risk, Judge Says

(July 9, 2018, 12:00 PM EDT) -- BLUEFIELD, W. Va. — A West Virginia federal judge on July 5 granted judgment for the distributors of Abilify, finding that the drug’s label explicitly warned about the risk of tardive dyskinesia that the plaintiff claims was caused by the atypical antipsychotic drug (Donald N. Proffitt, Jr., et al. v. Bristol-Myers Squibb Company, et al., No. 4391, S.D. W.Va., 2018 U.S. Dist. LEXIS 111895)....

Attached Documents

Related Sections